Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069

NCT01100047 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: AZD5069
DRUG: Placebo

Sponsor

AstraZeneca